Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Comment by smpt88on Jul 04, 2018 3:49pm
150 Views
Post# 28268967

RE:Takeover offer or Partnership?

RE:Takeover offer or Partnership?Whatever is cooking behind the scene has a great aroma, just look at the stock price going up since last month. GLTA.
DrHoliday wrote: It wouldn't surprise me at all if the company was in partnership talks at this time,
for the express purpose of bringing Oral B Amphotericin to market as quickly as possible.
Such a partnership would help to fast-track phase 2 trial testing. It is now July, and ICO is on the radar of big pharma. Production, marketing and distribution rights could be granted to the right partner with the capital backing to develop this multi billion dollar market share worldwide.

Talk of a takeover at the 75 cent level would likely be rejected as insufficient given that Oral B Amphotericin is not the only drug in the development pipeline. Is this just a rumor or has someone spilled the beans? In any case, it would be advisable to keep such information very confidential before being made public.
ICO owns the patent rights, and is in control here.
You should all reread the DoubleBank recommendation that just came out.

Buckle your seatbelt, because this rocket is on the launchpad, and shorty will get squeezed big time and eaten alive by a lion.


DOC.



<< Previous
Bullboard Posts
Next >>